Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis

Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with increased risk in patients with metabolic syndrome. There are no FDA-approved treatments, but FXR agonists have shown promising results in clinical studies for NAFLD management. In addition to FXR, fibroblast grow...

Full description

Bibliographic Details
Main Authors: Francois Moreau, Bruna Brasil Brunao, Xiang-Yu Liu, Frederic Tremblay, Kevin Fitzgerald, Julian Avila-Pacheco, Clary Clish, Ronald C. Kahn, Samir Softic
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:Journal of Lipid Research
Subjects:
fibroblast growth factor receptor 4
farnesoid X receptor
cholesterol
bile acids
liver steatosis
NAFLD
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227522001572

Internet

http://www.sciencedirect.com/science/article/pii/S0022227522001572

Similar Items